GENENTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
Study to Investigate the Safety, Pharmacokinetics, and Immunogenicity of Subcutaneous MCAF5352A in Healthy Volunteers
- First Posted Date
- 2011-11-28
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT01480310
Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-0941 Following Single Oral Dose Administration in Healthy Male Subjects
- First Posted Date
- 2011-11-18
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT01474668
Study to Determine the Effect of Ketoconazole on the Pharmacokinetics of GDC-0980
- First Posted Date
- 2011-11-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT01473316
A Study of DMOT4039A in Participants With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer
Phase 1
Completed
- Conditions
- Ovarian Cancer
- Interventions
- Drug: DMOT4039A
- First Posted Date
- 2011-11-10
- Last Posted Date
- 2017-01-10
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 71
- Registration Number
- NCT01469793
Study to Evaluate the Long-term Safety of Etrolizumab in Participants With Moderate to Severe Ulcerative Colitis
- First Posted Date
- 2011-10-28
- Last Posted Date
- 2020-02-10
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 121
- Registration Number
- NCT01461317
- Locations
- 🇺🇸
University of California, San Diego, La Jolla, California, United States
🇺🇸Atlanta Gastroenterology Associates, Atlanta, Georgia, United States
🇺🇸Long Island Clin Rsch Asc, LLP, Great Neck, New York, United States
A Study of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
- First Posted Date
- 2011-10-20
- Last Posted Date
- 2016-08-11
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT01455493
A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)
Phase 3
Completed
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2011-10-20
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 494
- Registration Number
- NCT01456325
Study of GDC-0980 Versus Everolimus in Participants With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following Vascular Endothelial Growth Factor- (VEGF) Targeted Therapy
- First Posted Date
- 2011-09-28
- Last Posted Date
- 2016-08-10
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 85
- Registration Number
- NCT01442090
An Extension Study to Evaluate Safety and Tolerability of Ranibizumab in Macular Edema Secondary to Retinal Vein Occlusion (Cohort 2)
Not Applicable
Completed
- Conditions
- Macular EdemaRetinal Vein Occlusion
- Interventions
- First Posted Date
- 2011-09-28
- Last Posted Date
- 2012-01-10
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 608
- Registration Number
- NCT01442064
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor Therapy
Phase 2
Completed
- Conditions
- Breast Cancer
- Interventions
- Drug: GDC-0941 Matching PlaceboDrug: GDC-0980 Matching Placebo
- First Posted Date
- 2011-09-21
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 318
- Registration Number
- NCT01437566
© Copyright 2025. All Rights Reserved by MedPath